We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Galmed Pharmaceuticals Ltd | NASDAQ:GLMD | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0034 | 0.88% | 0.3885 | 0.38 | 0.3885 | 0.398999 | 0.3666 | 0.3963 | 19,241 | 19:40:49 |
| | |
Page
|
| |||
Prospectus Supplement | | | | | | | |
| | | | S-ii | | | |
| | | | S-1 | | | |
| | | | S-9 | | | |
| | | | S-53 | | | |
| | | | S-55 | | | |
| | | | S-89 | | | |
| | | | S-90 | | | |
| | | | S-91 | | | |
| | | | S-92 | | | |
| | | | S-101 | | | |
| | | | S-108 | | | |
| | | | S-108 | | | |
| | | | S-108 | | | |
| | | | S-109 | | | |
Prospectus | | | | | | | |
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 4 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 6 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 15 | | | |
| | | | 16 | | | |
| | | | 17 | | | |
| | | | 24 | | | |
| | | | 25 | | | |
| | | | 28 | | | |
| | | | 28 | | | |
| | | | 28 | | | |
| | | | 28 | | | |
| | | | 29 | | | |
| | | | 30 | | |
| | |
Placebo
|
| |
Aramchol
400mg |
| |
Aramchol
600mg |
| |||||||||
MRS – Absolute change from baseline in mean liver fat(1)
|
| | | | -0.09% | | | | | | -3.41% | | | | | | -3.18% | | |
| | | | | | | | | | | P=0.0450 | | | | | | P=0.0655 | | |
MRS responders – Reduction of ≥5% in absolute change from baseline(1)
|
| | | | 24.4% | | | | | | 36.7% | | | | | | 47.0% | | |
| | | | | | | | | | | P=0.0878 | | | | | | P=0.0279 | | |
NASH resolution without worsening of fibrosis(2)
|
| | | | 5% | | | | | | 7.5% | | | | | | 16.7% | | |
| | | | | | | | | | | P=0.4955 | | | | | | P=0.0514 | | |
NASH resolution(2)
|
| | | | 7.5% | | | | | | 12.5% | | | | | | 19.2% | | |
| | | | | | | | | | | P=0.2237 | | | | | | P=0.0462 | | |
Fibrosis improvement (≥1 stage) without worsening of NASH(2)
|
| | | | 17.5% | | | | | | 21.3% | | | | | | 29.5% | | |
| | | | | | | | | | | P=0.8425 | | | | | | P=0.2110 | | |
Progression to Cirrhosis (Post-Hoc Analysis) worsening of
NASH(2) |
| | | | 7.5% | | | | | | 7.5% | | | | | | 1.3% | | |
| | | | | | | | | | | P=0.5693 | | | | | | P=0.1008 | | |
ALT (U/L) Change from baseline(3)
|
| | | | +11.82 | | | | | | -12.0 | | | | | | -17.3 | | |
| | | | | | | | | | | P=0.0002 | | | | | | P<0.0001 | | |
AST (U/L) Change from baseline(3)
|
| | | | +6.67 | | | | | | -7.20 | | | | | | -10.83 | | |
| | | | | | | | | | | p=0.0011 | | | | | | p<.0001 | | |
HbA1C Change from baseline(4)
|
| | | | +0.32 | | | | | | -0.04 | | | | | | -0.13 | | |
| | | | | | | | | | | p=0.0061 | | | | | | p=0.0008 | | |
| | |
September 30, 2020
(in thousands) (unaudited) |
| |||||||||
| | |
Actual
|
| |
As-Adjusted
|
| ||||||
Shareholders’ equity: | | | | | | | | | | | | | |
Ordinary shares, par value NIS 0.01 per share; Authorized 50,000,000 shares; Issued and outstanding: 21,312,043 shares (actual) and shares (as adjusted) as of September 30, 2020 and
|
| | | $ | 58 | | | | | $ | | | |
Additional paid-in capital
|
| | | $ | 178,938 | | | | | $ | | | |
Accumulated other comprehensive gain
|
| | | $ | 90 | | | | | $ | | | |
Accumulated deficit
|
| | | $ | (125,430) | | | | | $ | | | |
Total shareholders’ equity
|
| | | $ | 53,656 | | | | | $ | | | |
|
Public offering price per share
|
| | | | | | | | | $ | | | |
|
Net tangible book value per share as of September 30, 2020
|
| | | $ | 2.52 | | | | | | | | |
|
Increase in net tangible book value per share attributable to the offering
|
| | | $ | | | | | | | | | |
|
As adjusted net tangible book value per share as of September 30, 2020, after giving
effect to the offering |
| | | | | | | | | $ | | | |
|
Dilution per share to new investors in the offering
|
| | | | | | | | | $ | | | |
|
Legal fees and expenses
|
| | | $ | | | |
|
Accounting fees and expenses
|
| | | $ | | | |
|
Printing expenses
|
| | | $ | | | |
|
Miscellaneous
|
| | | $ | | | |
|
Total
|
| | | $ | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 4 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 6 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 15 | | | |
| | | | 16 | | | |
| | | | 17 | | | |
| | | | 24 | | | |
| | | | 25 | | | |
| | | | 28 | | | |
| | | | 28 | | | |
| | | | 28 | | | |
| | | | 28 | | | |
| | | | 29 | | | |
| | | | 30 | | |
| | |
December 31, 2017
|
| |||
| | |
(U.S. Dollars in
thousands, except share data) |
| |||
Shareholders’ equity: | | | | | | | |
Ordinary shares, par value NIS 0.01 per share; Authorized 50,000,000 shares; Issued and outstanding: 14,435,161 shares as of December 31, 2017
|
| | | $ | 40 | | |
Additional paid-in capital
|
| | | $ | 92,381 | | |
Accumulated other comprehensive loss
|
| | | $ | (7) | | |
Accumulated deficit
|
| | | $ | (76,619) | | |
Total shareholders’ equity
|
| | | $ | 15,795 | | |
| | |
Low
|
| |
High
|
| ||||||
Annual Information: | | | | | | | | | | | | | |
2014 (since March 13, 2014)
|
| | | $ | 4.58 | | | | | $ | 18.73 | | |
2015
|
| | | $ | 5.54 | | | | | $ | 13.50 | | |
2016
|
| | | $ | 2.78 | | | | | $ | 7.91 | | |
2017
|
| | | $ | 3.43 | | | | | $ | 9.78 | | |
Quarterly Information | | | | | | | | | | | | | |
First Quarter 2016
|
| | | $ | 3.50 | | | | | $ | 7.91 | | |
Second Quarter 2016
|
| | | $ | 3.88 | | | | | $ | 7.72 | | |
Third Quarter 2016
|
| | | $ | 3.53 | | | | | $ | 5.77 | | |
Fourth Quarter 2016
|
| | | $ | 2.78 | | | | | $ | 4.74 | | |
First Quarter 2017
|
| | | $ | 3.43 | | | | | $ | 5.79 | | |
Second Quarter 2017
|
| | | $ | 4.40 | | | | | $ | 7.09 | | |
Third Quarter 2017
|
| | | $ | 6.20 | | | | | $ | 9.39 | | |
Fourth Quarter 2017
|
| | | $ | 6.55 | | | | | $ | 9.78 | | |
Monthly Information: | | | | | | | | | | | | | |
September 2017
|
| | | $ | 7.52 | | | | | $ | 9.39 | | |
October 2017
|
| | | $ | 7.16 | | | | | $ | 9.59 | | |
November 2017
|
| | | $ | 6.55 | | | | | $ | 8.42 | | |
December 2017
|
| | | $ | 7.84 | | | | | $ | 9.78 | | |
January 2018
|
| | | $ | 9.01 | | | | | $ | 12.22 | | |
February 2018
|
| | | $ | 3.61 | | | | | $ | 10.79 | | |
|
SEC registration fees
|
| | | $ | 2,473 | | |
|
FINRA filing fee
|
| | | $ | 23,000 | | |
|
Legal fees and expenses
|
| | | $ | 30,000 | | |
|
Accountants fees and expenses
|
| | | $ | 15,000 | | |
|
Printing Fees
|
| | | $ | 2,200 | | |
|
Miscellaneous
|
| | | $ | 5,000 | | |
|
Total
|
| | | $ | 77,673 | | |
1 Year Galmed Pharmaceuticals Chart |
1 Month Galmed Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions